|
Feb 10
|
Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis
|
|
Dec 31
|
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60
|
|
Oct 11
|
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
|
|
Oct 9
|
Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide
|
|
Jul 26
|
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
|
|
May 9
|
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
|
|
Feb 13
|
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
|
|
Nov 29
|
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022
|